Eloxx Pharmaceuticals to Present at the 2019 BIO CEO and Investor Conference in New York City on Monday, February 11, 2019
February 04, 2019 07:00 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals to Participate in a Panel Discussion at the BIOTECH SHOWCASE™ in San Francisco on Wednesday, January 9, 2019
January 03, 2019 13:08 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals To Present at the 30th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018
November 20, 2018 07:00 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals To Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27, 2018
November 19, 2018 07:00 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals Reports Third Quarter 2018 Financial and Operating Results and Provides Business Update
November 08, 2018 07:00 ET
|
Eloxx Pharmaceuticals
ELX-02 has been granted an orphan drug designation by the European Medicines Agency (EMA) for Cystic Fibrosis Advancing several investigational drug candidates from our library in IND enabling...
Eloxx Pharmaceuticals Presents Positive New Data for Lead Investigational Drug, ELX-02, at the North American Cystic Fibrosis Conference (NACFC)
October 18, 2018 11:49 ET
|
Eloxx Pharmaceuticals
ELX-02 shows significant increases in CFTR function in Cystic Fibrosis patient-derived organoids bearing nonsense mutations in the CFTR gene ELX-02 demonstrated significant increases in CFTR mRNA,...
Eloxx Pharmaceuticals To Report Third Quarter 2018 Financial Results and Provide Business Update On November 8, 2018
October 16, 2018 18:16 ET
|
Eloxx Pharmaceuticals
Company management to host a webcast and conference call to provide a business update and review the financial results at 8:30 a.m. ET WALTHAM, Mass., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Eloxx...
Eloxx Pharmaceuticals To Present at the 8th Orphan Drugs & Rare Diseases Congress, the Oppenheimer Fall Summit, and the 2018 Cantor Global Healthcare Conference
September 24, 2018 07:00 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals Reports Second Quarter 2018 Financial and Operating Results and Provides Business Update
August 07, 2018 16:01 ET
|
Eloxx Pharmaceuticals
CTA approved in Belgium and IND open in the U.S. for investigational drug candidate, ELX-02 On track to initiate Phase 2 clinical trials in cystic fibrosis and cystinosis in 2018 Expanded Leadership...
Eloxx Pharmaceuticals To Present at the 38th Annual Canaccord Genuity Growth Conference
July 18, 2018 07:30 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., July 18, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...